newsfilter
← Latest News
GlobeNewswire·

Royalty Pharma Reports Third Quarter 2025 Results

Portfolio Receipts growth of 11% to $814 million; Royalty Receipts growth of 11%Net cash provided by operating activities of $703 millionRaised full year 2025 guidance: Portfolio Receipts expected to be $3,200 to $3,250